Maurice was pacing back and forth across his desk, occasionally hurling banana peels at a chart labeled “Free Cash Flow,” muttering something about “negative eighty-nine million” and “where does it all go?”
Let me tell you about a technology that genuinely fascinates me. Not “blockchain will solve everything” fascinates me. Not “AI will replace all workers” fascinates me. I’m talking about something that actually works at the cellular level—a way to trick your body into destroying the proteins that are slowly killing you. It’s called proteolysis targeting, and it’s real. It’s not hype. It’s not a pitch deck masquerading as science.
The company building this platform is Arvinas, Inc. (ticker: ARVN), a New Haven-based biotech founded in 2013 that’s developed something called PROTACs—proteolysis targeting chimeras. Fancy name. Simple concept: instead of trying to block a bad protein (the old way), you give your cells a molecular instruction that says “hey, destroy that one.” Your body already has a protein garbage disposal system. Arvinas just figured out how to point it at specific targets.
Now, here’s where I have to stop throwing bananas in celebration and start asking harder questions.
The Technology Is Real. The Business Model Is… Well.
I’ve been reading the recent conference calls. Arvinas presented at Barclays, TD Cowen, and Leerink in early March, and the narrative is genuinely compelling. Their lead candidate for breast cancer—vepdegestrant—is approaching an NDA filing in 2026. Their neurology program (ARV-102 for Parkinson’s and related diseases) is running phase 1 trials with data expected in the second half of 2026. They’ve got partnerships with pharma titans: Pfizer, Genentech, Roche, Bayer. Sixteen analysts cover this stock. The institutional confidence is there.
And then I looked at the balance sheet.
Revenue was down 84% year-over-year. Eighty-four percent. That’s not a decline. That’s a cliff. Free cash flow is negative $89 million annually. The company’s debt-to-equity ratio is 2.051—meaning they’re borrowing more than two dollars for every dollar of equity they have. They’re burning through cash like a chimp with a blowtorch in a banana grove.
Here’s the thing about biotech: phase 1 data doesn’t pay bills. NDA filings don’t pay bills. Only approved drugs that sell make money. And Arvinas, right now, is in that brutal middle ground where they’ve proven the technology works in humans, but they haven’t proven it works well enough—and sells well enough—to justify the burn rate.
So What’s the Bull Case?
Vepdegestrant for breast cancer is potentially enormous. The estrogen receptor (ER) pathway has been targeted for decades, but most existing drugs are degraders or antagonists. A PROTAC that actually removes the receptor from the cell is theoretically better. If vepdegestrant’s Phase 2 data (now running) shows improved efficacy or tolerability, and the NDA filing happens in 2026, you’re looking at a drug that could be on the market by 2027-2028. In a $50 billion breast cancer market, a new approach with novel efficacy could be worth billions.
ARV-102 for Parkinson’s disease is equally intriguing. Leucine-rich repeat kinase 2 (LRRK2) is a validated target. A protein degrader that removes mutant LRRK2 in the brain could actually slow neurodegeneration, not just manage symptoms. If phase 1 data shows tolerability and target engagement in the CNS (the hardest problem in neurobiology), this becomes a late-stage program worth billions.
The PROTAC platform itself is real. This isn’t aspirational biology. They’ve demonstrated that you can get these molecules into cells, recruit the right protein disposal machinery, and degrade specific targets. Pfizer and Roche wouldn’t be collaborating if it was vaporware.
And the valuation, on the surface, looks cheap. $652 million market cap. If vepdegestrant alone reaches peak sales of even $1-2 billion (conservative for a novel breast cancer drug), the stock is underpriced. If ARV-102 hits, you’re looking at a multi-billion-dollar franchise.
So the bull case is: you’re buying a dollar for 30 cents, betting that clinical data in H2 2026 validates the technology, and that partnered programs or approved drugs start generating meaningful revenue by 2027-2028.
Now Let Me Tell You What Keeps Me Up at Night
Phase 1 data is not Phase 3 data. I know this sounds obvious, but I watch investors get seduced by early-stage biotech all the time. “The phase 1 showed target engagement!” Yes. And phase 3 shows whether patients actually feel better, or whether side effects make the drug unusable. Arvinas hasn’t shown that yet. Not for vepdegestrant. Not for ARV-102. Not for anything.
The revenue collapse suggests that previous programs either failed or were divested. The company’s cash burn is accelerating despite the platform being “validated.” That tells me they’re investing heavily in new programs, which is necessary but also risky. More programs = more shots on goal, but also more capital required.
Interest rates are a real problem for biotech right now. The Fed isn’t cutting rates aggressively. Biotech funding is tightening. Arvinas has a debt-to-equity ratio of 2.051. If they need to raise capital—and pre-revenue biotech companies always do—they’ll either dilute shareholders or take on debt at worse terms. That $8.5 stop loss in the recommendation doesn’t feel aggressive; it feels realistic if capital raises happen at lower prices.
There’s also a sector rotation risk I can’t ignore. Biotech has underperformed for 18 months. If broader market conditions deteriorate, or if interest rates spike, investors will flee speculative biotech for established pharma with cash flow. ARVN has a beta of 1.976—nearly twice the market’s volatility. In a sector downturn, this stock could crater.
And then there’s the clinical execution risk, which is the most obvious but somehow easy to gloss over. Phase 2 trials can fail. Data can be disappointing. Side effects can emerge. The Phase 1 data for vepdegestrant hasn’t been fully detailed in a peer-reviewed journal (as far as I can tell). Conference presentations are marketing. Real science is in the data.
The short ratio is 4.61—meaning 4.61 days of average volume is sold short. That’s not extreme, but it suggests some serious bears are betting on a decline. When short interest is that high, it also means the stock is vulnerable to short squeezes, which can create artificial rallies that suck in momentum traders before crashing.
The Macro Picture
Biotech is cyclical. Right now, we’re in a tightening cycle. Rates are sticky higher. Venture funding is down. IPO windows are mostly closed. Companies that can’t reach profitability in 18-24 months are under pressure. Arvinas doesn’t have 18-24 months of runway at current burn rates without capital raises.
That said, if vepdegestrant hits in late 2026, and partnered programs (Pfizer, Roche, Bayer) start generating milestone payments, the narrative flips. Suddenly it’s not “how long until the money runs out?” It’s “this is a real company with real revenue coming.” That’s the inflection point the stock is pricing in right now.
Global biotech markets are also consolidating. Mergers and acquisitions are happening. If vepdegestrant data looks good, a large pharma could acquire Arvinas for $3-5 billion. That’s not a home run, but it’s a respectable exit for shareholders at current prices. And the partnered programs (with Pfizer, Roche, etc.) give those companies optionality—they could move fast on acquisition if the science validates.
What This Stock Actually Is
ARVN is not a company. It’s a lottery ticket with good odds and real science behind it. You’re not buying a business. You’re buying a bet that two specific trials (vepdegestrant Phase 2 and ARV-102 Phase 1) return impressive data in H2 2026, and that the market rewards that data with a repricing upward.
The entry point at $10 is reasonable if you have a three-to-five-year time horizon and can stomach a 50% drawdown. The target of $15 assumes vepdegestrant data is good and the market gives credit for a 2027-2028 approval pathway. The stop loss at $8.5 is appropriate if data disappoints or capital raises happen at desperation prices.
But here’s what I’m honestly wrestling with: the recommendation says “medium-term” and “high risk,” which is honest. But it’s also just saying “this is a biotech slot machine where you pull the handle and see if 2026 data comes up sevens.” That’s not wrong. That’s just what biotech is. If you’re okay with that, fine. If you need your portfolio to sleep at night, this isn’t your stock.
The Verdict
Arvinas has real technology, real partnerships, real catalysts coming in 2026, and a valuation that has upside if those catalysts hit. It also has a balance sheet on fire, clinical execution risk, sector headwinds, and a short-term price target that assumes a lot of things go right simultaneously. The technology is genuinely interesting. The business is genuinely fragile.
This is a “yes, but” stock. Yes, the PROTAC platform is real. But the company is burning $89 million a year and has negative revenue growth. Yes, 2026 catalysts are coming. But phase 2 breast cancer data and phase 1 neurology data are not guaranteed victories. Yes, Pfizer and Roche are partners. But partnerships can be dissolved if programs underperform.
If you believe in the science and can afford to lose half your money while waiting for late 2026 data, this is a calculated bet worth considering. If you need certainty or near-term profitability, walk away.
Maurice adjusted his tiny tie, set down the banana peel, and nodded slowly. “The fruit is real,” he said. “But the tree is still being planted.”
Disclaimer: Trained Market Money, Maurice, and our entire primate analysis team provide entertaining market commentary only. While Maurice’s Monkey Momentum Index™ and banana-based technical analysis have shown mysterious accuracy, they should never be considered financial advice. All investment decisions should be made in consultation with qualified financial professionals, not monkeys—no matter how impressive their fruit-throwing abilities may be. For real financial advice, please consult your financial advisor, who probably doesn’t accept bananas as payment.
Coming next week: We’re peeling back the layers on a semiconductor play that’s got Maurice swinging from the chandelier with excitement—until he reads the geopolitical risk section. Can a fabless designer survive the chip wars?
Maurice’s parting wisdom: “A platform is only as strong as its ability to generate revenue. Until then, it’s just a really expensive scientific experiment.”
Trained Market Monkey 